Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

被引:50
|
作者
Lian, Shu [1 ]
Xie, Xiaodong [1 ]
Lu, Yusheng [1 ,2 ]
Jia, Lee [1 ,2 ]
机构
[1] Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fuzhou, Fujian, Peoples R China
[2] Minjiang Univ, Inst Oceanog, Marine Drug R&D Ctr, Xiyuangong Rd, Fuzhou 350108, Fujian, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2019年 / 12卷
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
CD47; immune therapy; biological target; immune checkpoint; INTEGRIN-ASSOCIATED PROTEIN; SIRP-ALPHA; T-CELL; TARGETING CD47; POOR-PROGNOSIS; STEM-CELLS; CANCER; MIGRATION; BLOCKADE; PHAGOCYTOSIS;
D O I
10.2147/OTT.S220196
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The success of cancer immunotherapy on recognition checkpoints for killing cancer cells has raised a great interest of scientists in understanding new and old methods of immunotherapeutic. CD47 (cluster of differentiation 47) is a cell surface glycoprotein and widely expressed on cells, which belongs to the immunoglobulin (Ig) superfamily as a cell membrane receptor which serves in immune therapy. CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-alpha, also named CD172 alpha or SHPS-1) which may escape from immune cells such as macrophage and T cells. Meanwhile, tumor cells express high CD47 protein which may secrete exosomes with high CD47 expression. The high CD47 expression-exosomes could serve the tumor metastasis process and provide transfer convenience for tumors on the microenvironment. CD47 on cancer cells can also affect the migration and invasion of cells. The high CD47 expression on tumor or CTC (circulating tumor cell) surface means the stronger migration and invasion and makes them escape from immune cells for phagocytosis such as T cells, NK (natural killer) cells and macrophage, which could be used for diagnosis and prognosis on cancer patients. Meanwhile, targeting CD47 combined with other biomarkers such as EpCAM (epithelial cell adhesion molecule), CD44, etc on cancer surface could be used to isolate CTCs from patients' blood. In terms of treatment, anti-CD47 antibody combined with another antibody such as anti-PD-L1 (programmed death-ligand 1) antibody or drugs such as rituximab, DOX or oxaliplatin also has better therapeutic effects and antitumor function to tumors. Using nanomaterials as an intermediary for CD47-related immune therapy could greatly increase the therapeutic effect and overcome multiple biological barriers for anti-CD47 antibody in vivo. In this review, we discuss the important role and the function of CD47 in tumor metastasis and also provide a reference for related research.
引用
收藏
页码:9105 / 9114
页数:10
相关论文
共 50 条
  • [1] Is CD47 an innate immune checkpoint for tumor evasion?
    Liu, Xiaojuan
    Kwon, Hyunwoo
    Li, Zihai
    Fu, Yang-xin
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 7
  • [2] Is CD47 an innate immune checkpoint for tumor evasion?
    Xiaojuan Liu
    Hyunwoo Kwon
    Zihai Li
    Yang-xin Fu
    [J]. Journal of Hematology & Oncology, 10
  • [3] SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
    Veillette, Andre
    Chen, Jun
    [J]. TRENDS IN IMMUNOLOGY, 2018, 39 (03) : 173 - 184
  • [4] CD47 blockade as another immune checkpoint therapy for cancer
    Vonderheide, Robert H.
    [J]. NATURE MEDICINE, 2015, 21 (10) : 1122 - 1123
  • [5] CD47 blockade as another immune checkpoint therapy for cancer
    Robert H Vonderheide
    [J]. Nature Medicine, 2015, 21 : 1122 - 1123
  • [6] CD47: Beyond an immune checkpoint in cancer treatment
    Bian, Hui-Ting
    Shen, Yi-Wen
    Zhou, Yu-Dong
    Nagle, Dale G.
    Guan, Ying-Yun
    Zhang, Wei-Dong
    Luan, Xin
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (05):
  • [7] The SIRPα-CD47 immune checkpoint in NK cells
    Deuse, Tobias
    Hu, Xiaomeng
    Agbor-Enoh, Sean
    Jang, Moon K.
    Alawi, Malik
    Saygi, Ceren
    Gravina, Alessia
    Tediashvili, Grigol
    Nguyen, Vinh Q.
    Liu, Yuan
    Valantine, Hannah
    Lanier, Lewis L.
    Schrepfer, Sonja
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (03):
  • [8] Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective
    Yu-Chi Chen
    Wei Shi
    Jia-Jie Shi
    Jin-Jian Lu
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1 - 14
  • [9] Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective
    Chen, Yu-Chi
    Shi, Wei
    Shi, Jia-Jie
    Lu, Jin-Jian
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 1 - 14
  • [10] SIRP? DEFICIENT CAR-MACROPHAGES EXHIBIT ENHANCED ANTI-TUMOR FUNCTION AND BYPASS THE CD47 IMMUNE CHECKPOINT
    Sloas, Chris
    Gabbasov, Rashid
    Anderson, Nicholas
    Abramson, Sascha
    Klichinsky, Michael
    Ohtani, Yumi
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A152 - A152